Clinical trial
Effectiveness Of Liposomal Bupivacaine Stellate Ganglion Blockade In Preventing Atrial Fibrillation After Isolated Coronary Artery Bypass Grafting Surgery: A Randomized Placebo-Controlled Trial
NCT07570940 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Effectiveness Of Liposomal Bupivacaine Stellate Ganglion Blockade In Preventing Atrial Fibrillation After Isolated Coronary Artery Bypass Grafting Surgery: A Randomized Placebo-Controlled Trial
- Lead sponsor
- Mayo Clinic
- Phase
- Phase 4
- Overall status
- Not yet recruiting
- Start date
- September 14, 2026
- Completion date
- September 30, 2030
- Enrollment
- 450 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.